Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea
· Delayed Price · Currency is KRW 46,200
-1,300 (-2.74%)
Last updated: Jun 26, 2025
Next Biomedical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Net Income | 2,794 | 2,860 | -7,522 | -5,732 | -16,645 | -24,477 | Upgrade
|
| Depreciation & Amortization | 494.76 | 492.36 | 467.32 | 463.41 | 433.53 | 573.79 | Upgrade
|
| Loss (Gain) From Sale of Assets | -4.24 | -4.24 | - | -5.29 | -69.58 | -0.1 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 38.72 | 0.8 | 27.31 | Upgrade
|
| Loss (Gain) From Sale of Investments | -264.91 | -113.58 | -133.56 | 102.48 | 65.86 | 34.61 | Upgrade
|
| Stock-Based Compensation | 2,078 | 2,107 | 1,486 | 310.27 | 324.19 | 374.74 | Upgrade
|
| Other Operating Activities | -6,025 | -6,005 | 2,492 | -924.41 | 10,046 | 19,420 | Upgrade
|
| Change in Accounts Receivable | -561.98 | -876.88 | -617.38 | -199.44 | -14.62 | -26.57 | Upgrade
|
| Change in Inventory | 86 | -366.66 | -228.8 | -626.88 | 660.13 | 50.45 | Upgrade
|
| Change in Accounts Payable | -187.78 | -44.78 | 13.14 | 40.91 | -5.08 | -29.18 | Upgrade
|
| Change in Other Net Operating Assets | 1,155 | 752.12 | -117.41 | -1,676 | -192.62 | 1,162 | Upgrade
|
| Operating Cash Flow | -436.34 | -1,201 | -4,160 | -8,208 | -5,396 | -2,890 | Upgrade
|
| Capital Expenditures | -502.91 | -439.39 | -64.54 | -195.07 | -704.65 | -1,113 | Upgrade
|
| Sale of Property, Plant & Equipment | 4.27 | 4.27 | - | 19.47 | 380 | 0.68 | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | - | - | -69.59 | -42.5 | Upgrade
|
| Investment in Securities | -25,923 | -25,626 | 4,171 | -10,785 | -714.73 | -3,085 | Upgrade
|
| Other Investing Activities | -665.43 | -299.43 | 0.01 | 16.16 | 13.72 | 18.03 | Upgrade
|
| Investing Cash Flow | -27,087 | -26,361 | 4,106 | -10,945 | -1,095 | -4,222 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 2,400 | 3,200 | Upgrade
|
| Long-Term Debt Issued | - | 369 | 931 | 500 | - | - | Upgrade
|
| Total Debt Issued | 369 | 369 | 931 | 500 | 2,400 | 3,200 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -1,230 | -25 | Upgrade
|
| Long-Term Debt Repaid | - | -939.53 | -441.66 | -451.4 | -439.48 | -455.14 | Upgrade
|
| Total Debt Repaid | -977.67 | -939.53 | -441.66 | -451.4 | -1,669 | -480.14 | Upgrade
|
| Net Debt Issued (Repaid) | -608.67 | -570.53 | 489.34 | 48.6 | 730.52 | 2,720 | Upgrade
|
| Issuance of Common Stock | 28,965 | 28,920 | 484.29 | 46.56 | - | - | Upgrade
|
| Other Financing Activities | -0 | -0 | -0 | -0 | -0 | - | Upgrade
|
| Financing Cash Flow | 28,356 | 28,349 | 973.63 | 95.17 | 21,728 | 2,720 | Upgrade
|
| Foreign Exchange Rate Adjustments | 306.34 | 260.79 | -31.74 | 55.26 | 39.87 | -89.87 | Upgrade
|
| Net Cash Flow | 1,139 | 1,048 | 888.07 | -19,002 | 15,276 | -4,481 | Upgrade
|
| Free Cash Flow | -939.25 | -1,640 | -4,225 | -8,403 | -6,101 | -4,003 | Upgrade
|
| Free Cash Flow Margin | -8.58% | -17.18% | -86.53% | -300.65% | -269.08% | -177.05% | Upgrade
|
| Free Cash Flow Per Share | -119.92 | -221.77 | -672.87 | -1353.18 | -1260.87 | -935.17 | Upgrade
|
| Cash Interest Paid | 615.58 | 524.36 | 572.14 | 354.01 | 241.79 | 243.93 | Upgrade
|
| Cash Income Tax Paid | 25.9 | -6.46 | 63.92 | -1.76 | 15.73 | 3.2 | Upgrade
|
| Levered Free Cash Flow | -2,195 | -3,155 | -3,756 | -6,103 | -31,008 | 22,536 | Upgrade
|
| Unlevered Free Cash Flow | -1,885 | -2,830 | -3,397 | -5,877 | -30,125 | 23,495 | Upgrade
|
| Change in Net Working Capital | -291.54 | 775.73 | 666.26 | 2,611 | 25,536 | -27,003 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.